Altimmune to Participate in the Leerink Global Healthcare Conference

GAITHERSBURG, Md., March 03, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company, today announced that members of the Company’s management team will participate in a fireside chat at the Leerink Global Healthcare Conference. Details are as follows:

The session will be webcast and can be accessed by visiting the Events section of the Altimmune website.

About Altimmune

Altimmune is a late clinical-stage biopharmaceutical company focused on developing innovative next-generation peptide-based therapeutics. The Company is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity and MASH. For more information, please visit www.altimmune.com.

Follow @Altimmune, Inc. on LinkedIn
Follow @AltimmuneInc on Twitter

Company Contact:
Greg Weaver
Chief Financial Officer
Phone: 240-654-1450
[email protected]

Investor Contact:
Lee Roth
Burns McClellan
Phone: 646-382-3403
[email protected]

Media Contact:
Danielle Cantey
Inizio Evoke, Biotech
Phone: 619-826-4657
[email protected]

This press release was published by a CLEAR® Verified individual.

You May Also Be Interested In

• BNP PARIBAS GROUP: SUDAN LITIGATION STATEMENT FROM BNP PARIBAS
• AG AL's Gwen Snatches Esports World Cup Club Championship Glory In Unbelievable Trackmania Final
• Latest Crypto News: Bitcoin Rips Past $77K, Cardano Turns Bullish – Is Apeing Whitelist the Next Move for Traders?